Abstract Library

Welcome to the open-access search for all ENETS abstracts presented at the Annual ENETS Conferences.

Everyone can browse the library to find basic information on abstracts. To get full access to each entry, you will be asked to log in to your myENETS account.

 

Please note:

Participants of the 2025 ENETS Conference enjoy full access to the 2025 conference digital resources through myENETS: the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more.

Log in to myENETS

ENETS Abstract Search

#2800 Thymosin Beta 4 Is an Autocrine Mitogen for Neuroendocrine Tumour Cells

Introduction: The most commonly used NET marker chromogranin A, has a sensitivity between 60-90% and a specificity of less than 50%, hence better NET markers are needed. Previous secretome analysis using BON1, NCI-H727 and SHP-77 cell lines has led to the discovery of various candidate NET markers. One such marker is Thymosin Beta 4 (TB4). TB4 is a small 43 amino acid intracellular peptide first isolated from bovine thymus tissue.TB4 or its oxidised form TB4SO are thought to play a role in various aspects of cancer biology including tumour invasion, metastasis and apoptosis.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author:

Authors: Balasundaram P, Beaumont N, Liang S, Cuenco J, Lu X,

Keywords: neuroendocrine tumour, biomarkers, signalling,

#1856 Relationship Between Symptoms and HRQoL Benefits in Patients (pts) with Carcinoid Syndrome (CS): A Post-Hoc Analysis of Telotristat Ethyl (TE) TELESTAR Trial

Introduction: TELESTAR previously demonstrated the efficacy and safety of TE in pts with CS experiencing >4 Bowel Movements (BM) per day despite stable-dose somatostatin analog therapy. Significantly higher rates of Durable Response (DR, predefined as Bowel Movement (BM) frequency reduction ≥30% from baseline for ≥50% of the 12 week double blind period) were observed with TE (TE 250mg: 44%, TE 500mg: 42%) vs placebo (20%).

Conference: 14th Annual ENETSConcerence (2017)

Presenting Author: Cella D

Authors: Cella D, Beaumont J, Hudgens S, Marteau F, Feuilly M,

Keywords: telotristat ethyl, HRQoL, carcinoid syndrome,

#45 Neuroendocrine tumor disease state and RAND-36 health-related quality of life scores

Introduction: Health-related quality of life (HRQL) can be disrupted in patients with malignancies.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Phan A, Beaumont J, Liu Z, Choi S, Cella D,

Keywords: neuroendocrine tumor, health-related quality of life, carcinoid syndrome,

#44 Somatostatin analogue therapy and RAND-36 health-related quality of life scores in patients with neuroendocrine tumors

Introduction: Somatostatin analogues (SSAs) are used in patients with neuroendocrine tumors (NETs) for the management of carcinoid syndrome and/or delay of disease progression.

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author:

Authors: Yao J, Beaumont J, Choi S, Cella D, Liu Z,

Keywords: neuroendocrine tumor, health-related quality of life, somatostatin analogue, carcinoid syndrome,

#43 Relationship between neuroendocrine tumor-related symptoms and RAND-36 health-related quality of life scores

Introduction: Neuroendocrine tumors (NETs) can secrete hormones that cause flushing and diarrhea (carcinoid syndrome) and disrupt health-related quality of life (HRQL).

Conference: 7th Annual ENETSConcerence (2010)

Presenting Author: Yao J

Authors: Beaumont J, Liu Z, Choi S, Yao J, Phan A,

Keywords: neuroendocrine tumor, health-related quality of life, diarrhea, flushing,